Vabysmo (faricimab) is the first bispecific antibody designed for the eye. It targets and inhibits two signalling pathways linked to a number of vision-threatening retinal conditions by neutralising angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). Ang-2 and VEGF-A contribute to vision loss by destabilising blood vessels, causing new leaky blood vessels to form and increasing inflammation. By blocking both pathways involving Ang-2 and VEGF-A, Vabysmo is designed to stabilise blood vessels.

Vabysmo is now approved in the European Union and nine other countries around the world, including the US, Japan, and the UK, for people living with "wet" age-related macular degeneration and diabetic macular edema.